Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s Maraviroc Unanimously Recommended For Accelerated Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

However, members of FDA’s Antiviral Drugs Advisory Committee voice numerous concerns, recommending additional data or analysis for full approval of the CCR5 antagonist.
Advertisement

Related Content

Pfizer’s Selzentry Wins FDA Approval For HIV
Pfizer’s Selzentry Wins FDA Approval For HIV
Schering-Plough, Incyte Report Positive Mid-Stage Data For CCR5 Antagonists
Schering-Plough, Incyte Report Positive Mid-Stage Data For CCR5 Antagonists
Pfizer’s Maraviroc Deemed “Approvable” By FDA
Pfizer’s Maraviroc Deemed “Approvable” By FDA
Incyte’s CCR5 Antagonist Has “Meaningful Advantages” Over Pfizer’s Maraviroc, Firm Says
Review Of Pfizer’s Maraviroc Will Reflect CCR5 Antagonist Class Safety Issues
Review Of Pfizer’s Maraviroc Will Reflect CCR5 Antagonist Class Safety Issues
Schering’s Vicriviroc R&D To Focus On Treatment-Experienced HIV Patients

Topics

Advertisement
UsernamePublicRestriction

Register

PS065953

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel